Kuznicki Law is investigating the proposed merger of Infinity Pharmaceuticals, Inc. (the “Company”) (NasdaqGS: INFI) with MEI Pharma, Inc. (NasdaqCM: MEIP). Under the terms of the proposed transaction, Infinity shareholders will end up owning 42.0% of the outstanding equity of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Infinity Pharmaceuticals, Inc. (NasdaqGS: INFI) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.